The World Health Organization has released its latest recommendations for the composition of seasonal influenza vaccines for the 2026–2027 Northern Hemisphere season. The guidance, based on global surveillance of circulating influenza viruses, helps vaccine manufacturers and health authorities prepare formulations months ahead of the next flu season.
Influenza viruses evolve continuously through genetic mutations, meaning vaccines must be updated regularly to remain effective. To address this, the WHO convenes international experts twice a year to review epidemiological, virological and serological data from around the world. Based on this evidence, they recommend which viral strains should be included in vaccines for upcoming influenza seasons in each hemisphere.
These recommendations guide vaccine manufacturers globally, ensuring enough time for production and distribution before the seasonal vaccination campaigns begin.
The WHO decision relies heavily on the Global Influenza Surveillance and Response System (GISRS), a network of laboratories and public health institutions that monitor circulating influenza viruses worldwide. Experts analyse virus samples, genetic changes and patterns of disease spread to determine which strains are most likely to dominate in the next season.
The consultation that informed the 2026–2027 vaccine recommendations took place in February 2026, bringing together researchers, regulatory authorities, and vaccine manufacturers to evaluate global influenza activity and vaccine study results.
Seasonal influenza vaccines typically protect against three main virus strains: two influenza A subtypes (H1N1 and H3N2) and one influenza B virus. Updating these components helps ensure that vaccines match the viruses expected to circulate in the upcoming winter season.
For clinicians and public health professionals, the updated recommendations provide a critical roadmap for vaccination strategies, manufacturing timelines and regulatory approvals ahead of the 2026–2027 influenza season.
WHO officials stress that annual vaccination remains the most effective way to reduce influenza-related illness, hospitalisations and deaths. By continually adapting vaccine composition based on surveillance data, global health authorities aim to maintain strong protection against evolving influenza viruses.
The new recommendations will now guide national regulators and pharmaceutical companies as they begin production of vaccines for distribution later this year.
Read the full article here.